India, June 24 -- Glenmark Pharmaceuticals Ltd., a global research-driven pharmaceutical company, has launched TEVIMBRA® (tislelizumab) in India, following its approval by the Central Drugs Standard Control Organization (CDSCO). This marks Glenmark's entry into the immuno-oncology segment in India and a significant step in strengthening its innovative oncology portfolio.
TEVIMBRA®, developed by global oncology leader BeiGene (now BeOne Medicines), is an anti-PD-1 monoclonal antibody. It is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) as a first-line therapy in combination with chemotherapy, and as a second-line monotherapy for both NSCLC and esophageal squamous cell carcinoma (ESC...